For U.S. Residents Only

The International Society on Thrombosis and Haemostasis (ISTH) Guidelines

CABLIVI is the only FDA-approved treatment for aTTP in combination with PEX/ immunosuppression recommended by the ISTH*

img

The International Society on Thrombosis and Haemostasis (ISTH) Treatment Guidelines suggests using CABLIVI for patients experiencing their first episode or another aTTP episode.

The ISTH created a guideline for the treatment of TTP, including aTTP. The guideline helps doctors and other healthcare professionals to make informed treatment decisions for patients with aTTP. The ISTH is a global, not-for-profit organization of experts in this field. It has more than 5000 members in 100 countries.

*Recommendations based on laboratory testing and diagnosis.

Talk to your doctor about whether CABLIVI is right for you

Start Here to Learn More
IMPORTANT SAFETY INFORMATION
Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?
Add
IMPORTANT SAFETY INFORMATION
Who should not take CABLIVI?

Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.

What should I tell my healthcare team before starting CABLIVI?

Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.

What are the possible side effects of CABLIVI?

CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants. CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.

INDICATIONS:
What is CABLIVI?

CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Please see full Prescribing Information
Instructions for Use
Sharps Medical Waste Disposal (PDF)

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

TTP=thrombotic thrombocytopenic purpura.